OARSI - European market - 25 settembre 2010
Learning Objectives
* Review the actions of the various mediators (ie, cytokines, chemokines) associated with inflammation
* Understand the potential protective role of nitric oxide (NO) in the joint
* Summarize the results of clinical trials and meta-analyses of the impact of various nsNSAIDs, COX 2s, and analgesics on blood pressure
* Discuss the current research with CINODs and their potential benefit in the management of osteoarthritis patients
Agenda
12:30 – 12:35
Welcome and Introductions
Steven R. Goldring, MD
Symposium Chair
Chief Scientific Officer
Hospital for Special Surgery
New York, New York
12:35 – 13:00
Inflammation in Osteoarthritis
Steven R. Goldring, MD
13:00 – 13:25
Management of the Osteoarthritis Patient:
Should We Be More Focused on the
Cardiovascular Risks of Current Therapies?
Thomas F. Lüscher, MD, FRCP
Professor and Chairman
Cardiology and Cardiovascular Physiology
University Hospital Zurich
Zurich, Switzerland
13:25 – 13:50
Recent Advances in the Development
of Nitric Oxide Donor Drugs
Mauro Perretti, PhD, FBPharmacolS
Professor of Immunopharmacology
Senior Research Fellow, Arthritis Research Campaign
Centre Lead (joint), Centre for Biochemical Pharmacology
Deputy Director, William Harvey Research Institute
Barts and The London School of Medicine
Queen Mary University of London
London, UK
13:50 – 14:00
Q&A/Panel Discussion
Grantor
Medical Education Resources (MER) gratefully acknowledges NicOx, Inc, for its support of this program through an educational grant.
Sponsor
This activity is sponsored by MER.
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Education Resources (MER) and Innovations Consulting Group, LLC (ICG). MER is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
MER designates this educational activity for a maximum of 1.5 AMA PRA Category 1 credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in this activity.